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Gastric cancer is a leading cause of cancer related mortality, and current 
treatment outcomes for advanced disease remain poor. HER2 protein 
overexpression and gene amplification are significant biomarkers for 
identifying gastric cancer patients who possibly respond to HER2-targeted 
therapy using trastuzumab.  
The aim of this study was to identify prevalence rate of HER2 gene 
amplification/overexpression in a local population, and determine the 
concordance rate between IHC and FISH techniques. 
Formalin-fixed, paraffin-embedded sections of 43 adenocarcinoma specimens 
from 61 cases of gastric cancer patients were analyzed. Protein expression 
was assessed using immunohistochemistry and gene amplification was 
evaluated by fluorescence in situ hybridization. 
11.7% (5/43) and 7,5% (3/40) of gastric adenocarcinomas displayed HER2 
protein overexpression (score 3+/2+) and gene amplification, respectively. 
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1.1. Gastric cancer 
Gastric cancer has been described as early as 3000 BC in hieroglyphic inscriptions 
and papyri manuscripts from ancient Egypt. It is the fourth most common 
malignancy and one of the leading causes of cancer mortality worldwide [1]. 
Approximately 21,600 patients are diagnosed annually in the United States, of 
whom 10,990 are expected to die [2]. In Vietnam, gastric cancer is the fourth most 
common malignancy and the third leading cause of cancer death in both sexes [3]. 
The incidence of gastric cancer varies with different geographic regions. Rates are 
highest in Eastern Asia, Eastern Europe, and South America, while the lowest rates 
are in North America and parts of Africa. Over 70 percent of gastric cancers occur 
in developing countries. Gastric cancer is more common in men than in women, in 
both developed and developing countries [4]. 
 
Figure 1.1: Globocan 2012, Population fact sheets: Vietnam. Estimated age-
standardised incidence and mortality rates: both sexes [3] 
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Surgical resection is the cornerstone of treatment and can cure patients with early-
stage cancer. The survival rate of patients with advanced resectable gastric or 
gastroesophageal junction (GEJ) cancers, however, remains poor despite new 
treatment strategies, such as perioperative chemotherapy
 
or adjuvant 
chemoradiation [5]. In Western countries as well as Vietnam, most gastric cancer 
patients are diagnosed when the tumor is at an unresectable stage. For these 
patients, systemic chemotherapy is the main treatment option because it prolongs 
survival without quality of life compromise. Many single agents and combinations 
are used in the treatment of metastatic disease. Objective response rates change 
from 10% to 30% for single-agent therapy and 30% to 60% for combination 
regimens. Platinum compounds, fluoropyrimidines, antracyclines, and, recently, 
taxanes, irinotecan and vinorelbine are the most active drugs. Despite a large 
number of randomized trials, there is no consensus as to the best agent or regimen. 
In general, combination chemotherapy regimens provide higher response rates than 
do single agents, but this translates into only modestly longer durations of disease 
control and survival that are measured in weeks to a few months [6].  
Survival of patients with advanced gastric cancer treated with palliative 
chemotherapy remains low. New therapies are urgently needed. A better 
understanding of the molecular basis of cancer has contributed to the development 
of rationally designed molecular targeted therapies, which interfere with the 
signalling cascades involved in cell differentiation, proliferation, and survival. 
Several molecular targeting agents for patients at an unresectable stage are now 
under evaluation in international randomized studies [7], and trastuzumab, an anti-
HER2 monoclonal antibody, has been shown to exhibit antitumor activity against 
HER2-positive gastric cancers [8] 
1.2. HER2 protein and gene 
The human epidermal growth factor receptor family of receptors plays a central role 
in the pathogenesis and treatment of several human cancers. They regulate cell 
growth, survival, and differentiation by way of multiple signal transduction 
pathways and play a role in cellular proliferation and differentiation. This family is 
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composed of four members: HER1 (EGFR), HER2, HER3 (ErbB-3), and HER4 
(ErbB-4). All four HER receptors comprise a cysteine-rich extracellular ligand 
binding site, a transmembrane lipophilic segment, and an intracellular domain with 
tyrosine kinase catalytic activity. Epidermal growth factor receptor (EGFR, ErbB1, 
and HER1) was discovered by Carpenter et al at Vanderbilt University, USA, in 
1978 [9]. ErbB stands for its origin in the Erb-b gene responsible for avian 
erythroblastosis virus. The neu oncogene (also known as HER2, ErbB2, or p185) 
was discovered by a group of scientists at Massachusetts Institute of Technology, 
Rockefeller, and Harvard University [10]. These 4 receptors share the same 
molecular structure with an extracellular ligand-binding domain, a short 
transmembrane domain, and an intracellular domain with TK activity (excepting the 
HER3). The binding of different ligands to the extracellular domain initiates a 
signal transduction cascade that can influence many aspects of tumor cell biology, 
including cell proliferation, apoptosis, adhesion, migration, and differentiation. 
Ligand binding induces EGFR homodimerization as well as heterodimerization with 
other types of HER proteins. HER2 does not bind to any known ligand, but it is the 
preferred heterodimerization partner for other members of the HER family. The 
HER2 receptor is a 1255 amino acid, 185 kD transmembrane glycoprotein located 
at the long arm of human chromosome 17 (17q12) [11]. HER2 is expressed in many 
tissues including the breast, gastrointestinal tract, kidney, heart and its major role in 
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Figure 1.2: Signal Transduction by the HER Family 
As shown in Panel A, the four members of the HER family are HER1, HER2, HER3, 
and HER4. There are receptor-specific ligands for HER1, HER3, and HER4. An 
intracellular tyrosine kinase domain exists for HER1, HER2, and HER4. 
Phosphorylation of the tyrosine kinase domain by means of homodimerization or 
heterodimerization induces both cell proliferation and survival signaling. HER2 is 
the preferred dimerization partner for the other HER family members. The 
phosphorylated (activated) tyrosine residues on the intracellular domain of HER2 
activate the lipid kinase phosphoinositide 3-kinase (PI3-K), which phosphorylates a 
phosphatidylinositol that in turn binds and phosphorylates the enzyme Ak 
transforming factor (Akt), driving cell survival. In parallel, a guanine nucleotide 
exchange factor, the mammalian homologue of the son of sevenless (SOS), activates 
the rat sarcoma (RAS) enzyme that, in turn, activates receptor activation factor 
(RAF) and then the mitogen-activated protein kinase (MAPK) and mitogen 
extracellular signal kinase (MEK). MEK phosphorylates, among others, the MAPK, 
driving cellular proliferation. One of many other downstream effects is the 
production of vascular endothelial growth factor (VEGF) supporting 
angiogenesis[13] 
In carcinomas, HER2 acts as an oncogene, mainly because high-level amplification 
of the gene induces protein overexpression in the cellular membrane and subsequent 
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1.3. HER2 protein overexpression and HER2 gene amplification in gastric 
cancer 
Overexpression of HER2 in breast cancer, resulting in HER2-positive subtypes, is 
associated with very poor prognosis compared with HER2-negative breast cancer 
[15]. HER2-positive breast cancer is also associated with increased risk of local 
growth and distant metastasis. Many studies, including several conducted in Japan, 
have reported that HER2 is also present in other cancers, particularly in gastric 
cancer [16, 17]. Recent studies on prevalence of HER2 positivity in patients with 
gastric cancer revealed the frequency of HER2-positive gastric cancer ranging from 
6.0 to 36.6 % [18-22] (Table 1.1). Many studies, which determined HER2 
overexpression by IHC using monoclonal antibody (HercepTest) and/or gene 
amplification by FISH, have observed similar rates. In a Japanese series, Yano et al. 
reported that HER2 overexpression by IHC was found in 23% and gene 
amplification by FISH in 27% of 200 resected tumors [18]. Bang and coworkers 
reported that differences in HER2 expression were mainly attributed to the site of 
the primary tumor (gastric or gastroesophageal junction) and histological type 
(diffuse or intestinal) [8]. Gravalos and Jimeno in their study of 166 gastric cancer 
patients observed that HER2 overexpression was most commonly found in 
gastroesophageal junction (GEJ) tumors and tumors having intestinal type histology 
[23]. Other studies also confirmed a higher rate of HER2 positivity in GEJ tumors 
and intestinal subtype [8, 18]. The role of HER2 as a prognostic factor in gastric 
cancer has been controversial because some of the initial studies failed to find an 
association with prognosis [24]. Unlike in breast cancer, the studies in gastric 
cancer to date have yielded inconsistent findings regarding the prognostic relevance 
of HER2. Some showed that HER2 positivity was associated with a significantly 
worse prognosis [19, 25, 26], whereas others found no association between HER2 
status and prognosis [27, 28]. In a study of 260 gastric cancers, HER2 
overexpression was an independent negative prognostic factor and HER2 staining 
intensity was correlated with tumor size, serosal invasion, and lymph node 
metastases [29]. In a retrospective study of 108 cases, HER2 overexpression was 
associated with a poorer 10-year survival [30]. In another study, a significantly 
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poorer prognosis was observed in HER2-positive early gastric cancer in a series of 
226 patients [31]. Nakajima et al. considered that in early-stage tumors, HER2 
overexpression is the second poorest prognostic variable after nodal status [32]. In a 
Korean study, HER2 overexpression and gene amplification with semiquantitative 
standardized IHC staining, CISH and FISH were determined in 182 gastric cancer 
patients who underwent curative surgery [33]. Sixteen percent expressed HER2 
protein by IHC and HER2 gene amplification was detected in seven patients by 
CISH and FISH. Intestinal-type cancers exhibited higher rates of HER2 
amplification than did diffuse-type cancers (P<0.05). Tumors with HER2 
amplification were associated with poor mean survival rates (922 vs 3243 days) and 
5-year survival rates (21% vs 63%;P< 0.05). Age, TNM stage, and amplification of 
HER2 were found to be independently related to survival by multivariate analysis. 
Table 1.1: Prevalence of HER2 positivity in patients with gastric cancer 
Study Country n 




Takehana et al. 
[34] 
Japan 352 IHC2+/IHC3+ 8,2 
Tanner et al. [21] Finland 231 CISH+ 36.6 




Kim et al. [22] Korea 248 IHC3+ or IHC2+/FISH+ 6 




Yan et al. [36] China 145 IHC3+ or IHC2+/FISH+ 10,3 
Liu et al. [37] China 775 IHC3+ or IHC2+/FISH+ 12,1 
Tsapralis et al. [38] Greece 120 IHC2+/IHC3+ 16,6 
Terashima et al. 
[28] 
Japan 829 IHC3+ or IHC2+/DISH+ 9 
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1.4. Testing for HER2 and concordance between HER2 protein overexpression 
and gene amplification in gastric cancer 
Although several methods for HER2 testing have been developed, approximately 
20% of current HER2 testing may be inaccurate. Therefore, the American Society 
of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) 
have recommended guidelines in HER2 testing to ensure accuracy [40]. The two 
methods currently approved for HER2 testing are immunohistochemistry (IHC) and 
fluorescence in situ hybridization (FISH). In gastric cancers, heterogeneity of the 
HER2 genotype can lead to discrepancies in the results from IHC and FISH testing 
[41]. Tumor heterogeneity was seen in roughly 4.8% of samples with moderate or 
strong HER2 staining and was higher than what was experienced in breast cancer 
(1.4%) [42]. ASCO/CAP guidelines state that intratumoral heterogeneity may 
contribute to HER2 testing inaccuracy. Incomplete basolateral membrane HER2 
IHC staining is also more common in gastric cancer than in breast cancer. This is 
due to the higher frequency of glandular formations that occur in gastric tissue. In 
gastric tissue, the basolateral membrane is stained, not the luminal membrane 
resulting in the heterogeneity. Currently, there are no ASCO/CAP approved HER2 
testing guidelines for gastric cancer. Figure 1.3 shows consensus panel 
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Figure 1.3: Immunohistochemistry scoring for HER2 in gastric and gastro-
oesophageal junction cancer, by type of diagnostic specimen [8]. 
The National Comprehensive Cancer Network (NCCN) guidelines panel 
recommended that less than 3+ overexpression of HER2 by IHC should be 
additionally examined by FISH or other in situ hybridizationmethods. Gastric 
cancers with HER2 IHC overexpression of 3+ or FISH positive are considered 
positive and thus be treated with trastuzumab. Thus, HER2 3+ or FISH+/HER2 IHC 
1+, FISH+/HER2 IHC 2+, FISH +/HER2 IHC 3+ gastric cancer patients should be 
treated with trastuzumab. 
In breast cancer, it is generally thought that HER2 overexpression is mainly (95%) 
achieved via gene amplification (increased copies of the HER2 gene), thereby 
resulting in increased transcription of the gene, increased HER2 receptors on the 
cell membrane (protein overexpression), and increased cell proliferation [43]. For 
breast cancer, a standardization of the FISH and IHC assessments of HER2 protein  
overexpression and gene amplification has been introduced and the concordance 
rates between these two methods are ranged from 73% - 98% [44]. However, the 
concordance of protein expression and gene amplification of HER2 in gastric cancer 
have been controversial. Studies published in 1990–1991 did not report a high 
12 
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concordance between these two methods of assessment. In a series of 40 cases 
analyzed by Lemoine et al. [45], 26% were found to display elevated protein 
expression, but only 13% evidenced gene amplification. A similar result was also 
observed by Kameda et al. [46] who detected overexpression without amplification 
and considered that this may indicate that gene amplification may not be the 
primary mechanism by which the HER2 protein is overexpressed in gastric cancer. 
HER2 overexpression may occur by a number of different mechanisms, including 
transcriptional activation by other genes or post-transcriptional events [47]. 
Although some studies obtained concordance between HER2-protein 
overexpression by IHC and HER2 gene amplification by FISH or chromogenic in 
situ hybridization (CISH) [18, 33, 48, 49], an IHC scoring system for breast cancer 
was applied in these researches. Hofmann and coworkers noticed that the 
discrepancies between IHC and FISH were attributed to basolateral membranous 
immunoreactivity of glandular cells resulting in incomplete membranous reactivity 
and a higher rate of tumor heterogeneity in gastric cancer compared with breast 
cancer [41]. In addition, discrepancies in the results for HER2 testing between 
surgically resected tumors and matched biopsy specimens may also occur due to 
intratumor heterogeneity in gastric carcinoma tissue [41, 50]. They suggested a 
modified IHC scoring system for gastric cancer, which was used to pre-ToGA 
studies [41]. Recent studies report a high concordance between protein 
overexpression in IHC and amplification by FISH or CISH [35, 36, 51]. 
1.5. Targeting HER2 therapy: Trastuzumab 
HER2 status has become an important biomarker for identifying patients who could 
respond to HER2 targeting therapy using the humanized monoclonal antibody 
trastuzumab. Trastuzumab consists of two antigen-specific sites that bind to the 
juxtamembrane portion of the extracellular domain of the HER2 receptor and that 
prevent the activation of its intracellular tyrosine kinase. The remainder of the 
antibody is human IgG with a conserved Fc portion [13]. Antitumor mechanisms 
suggested for the therapeutic effect of trastuzumab are: (1) a direct antiproliferative 
effect by blockade of signalling pathways, down-modulation of the HER2 protein, 
13 
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and activation of apoptotic signals of the tumor cells, and (2) an indirect antitumor 
effect by antibody dependent cell mediated cytotoxicity (ADCC) activity [52, 53]. 
 
Figure 1.4: Potential Mechanisms of Action of Trastuzumab. 
The most well-documented potential mechanisms of action are shown in Panels B 
through F. Cleavage of the extracellular domain of HER2 leaves a membrane-
bound phosphorylated p95, which can activate signal-transduction pathways (Panel 
B). Binding of trastuzumab to a juxta-membrane domain of HER2 reduces shedding 
of the extracellular domain, thereby reducing p95 (Panel C). Trastuzumab may 
reduce HER2 signaling by physically inhibiting either homodimerization, as shown, 
or heterodimerization (Panel D). Trastuzumab may recruit Fc-competent immune 
effector cells and the other components of antibody-dependent cell-mediated 
cytotoxicity, leading to tumor cell death (Panel E). Additional mechanisms such as 
receptor down regulation through endocytosis have been postulated (Panel F) [13]. 
The benefit of trastuzumab in advanced HER2-positive adenocarcinoma of the 
stomach was addressed in the phase III ToGA trial, which compared standard 
chemotherapy with and without trastuzumab (8 mg/kg loading dose, then 6 mg/kg 
every three weeks until disease progression) [8]. The objective response rate was 
significantly higher with trastuzumab (47 versus 35 percent). At a median follow-up 
of 17.1 to 18.6 months, median overall survival (the primary endpoint) was 
significantly better with trastuzumab (13.8 versus 11.1 months). Exploratory 
analysis in subgroups defined by protein expression proposed that trastuzumab was 
14 
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most effective in prolonging survival in the subgroup of patients with IHC 3+ 
tumors, less effective in patients with IHC 2+ tumors, and ineffective in those with 
HER2 gene-amplified (ie, FISH-positive) but non protein-expressing (IHC 0 or 1+) 
tumors. Based upon these data, trastuzumab was approved [54], in combination 
with cisplatin and a fluoropyrimidine, for the treatment of patients with metastatic 
HER2-overexpressing gastric who have not received prior treatment for metastatic 
disease. Patients with advanced gastric cancer who are potential candidates for 
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2. AIM OF THE STUDY 
 
In Vietnam, gastric cancer is the fourth most common malignancy and the third 
leading cause of cancer death [3]. Most gastric cancer patients are diagnosed when 
the tumor is at an unresectable stage. For these patients, systemic chemotherapy is 
the main treatment option because it prolongs survival without quality of life 
compromise. Now, trastuzumab is approved for the treatment of patients with 
metastatic HER2-overexpressing gastric who have not received prior treatment for 
metastatic disease [54]. It is now recommended that all patients with gastric cancer 
should have their tumors tested for HER2 status at the time of initial diagnosis [55]. 
In Vietnam, there is little research on HER2 protein overexpression and gene 
amplification in gastric cancer. The use of trastuzumab for treatment of advanced 
gastric cancer is limit. Causes mainly due to difficulties in implementing the 
technique, especially in immunohistochemistry and fluorescence in situ 
hybridisation. So, we conducted this study with the following aims. 
1. Identify HER2 status in Vietnamese gastric cancer patients 
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3. MATERIALS AND METHODS 
3.1. Study sites 
This was a cross-sectional study and was conducted from March 2012 to June 2014, 
at following settings: 
 - Operation Theater A of Hue Central Hospital 
 - Gastrointestinal Endoscopic Center of Hue University Hospital 
- Anatomical Pathology Department of Hue University Hospital 
 - Medical genetic Department of Hue University of Medicine and Pharmacy 
 - Anatomical Pathology Department of Sassari University Hospital 
3.2. Sample collection 
Samples was collected from 03/2012 to 04/2014. We had total 61 samlples include: 
- 43 random surgical samples from patients that were diagnosed gastric 
cancer at Hue Centre Hospital 
- 18 biopsy samples that were histopathologically diagnosed gastric cancer at 
Hue Medical University Hospital 
- Patients who received perioperative chemotherapy in the past were 
excluded 
3.3. Slide preparation 
a. Fixation of specimens 
 - Fixative solution: 10% neutral-buffered formalin (equivalent to 4% 
formaldehyde solution) 
 - Fixative volume: 10-20 times greater than specimens volume 
 - Fixation time:  specimens were fixed no later than 20 minutes after taked 
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- Fixation duration:  
  + biopsy specimens: 6 - 8 hours 
  + surgical specimens: 8 - 48 hours 
b. Processing of specimens 
Following fixation, tissue specimens were processed by these protocol 
Table 3.1: Protocol for processing gastric specimens 
Steps Substances 
Time (minutes) 
Surgical specimen Biopsy specimen 
1 10% neutral-buffered formalin 30 10 
2 Disttiled water 30 5 
3 Alcohol 70% 60 10 
4 Alcohol 80% 90 10 
5 Alcohol 95% 90 15 
6 Alcohol 100% 120 20 
7 Alcohol 100% 120 20 
8 Alcohol 100 % 120 20 
9 Xylene 90 20 
10 Xylene 90 20 
11 Paraffin 60 20 
12 Paraffin 60 20 
13 Paraffin 60 20 
 
c. Embedding in paraffin wax 




 - Paraffin blocks were stored at room temperature for a long time 
3.4. Sectioning and Hematoxylin and Eosin (H&E) staining  
 - Section thickness 
+ H&E staining: 2 µm 
+ IHC: 5 µm  
18 
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+ FISH: 4 µm  
 - Mount on slide and perform H&E staining 
 - Interpret slides to determine the diagnosis of gastric adenocarcinoma, 
Lauren's classification (intestinal type vs diffuse type) [56] 
 - Mark (encircle) the largest possible area of tumor, excluding necrotic, 
inflammatory, or normal mucosa 
3.5. Immunohistochemical staining for HER2 protein 
We performed IHC staining for HER2 protein using PATHWAY anti-HER-2/neu 
(4B5) Rabbit Monoclonal Primary Antibody by Ventana Benchmark Ultra 
automatic staining system.  
a. Principles 
PATHWAY HER2 (4B5) is a rabbit monoclonal antibody, which binds to HER2 in 
paraffin-embedded tissue sections. The specific antibody can be localized by either 
a biotin conjugated secondary antibody formulation that recognizes rabbit 
immunoglobulins followed by the addition of a streptavidin-horseradish peroxidase 
(HRP) conjugate (iVIEW DAB Detection Kit) or a secondary antibody-HRP 
conjugate (ultraView Universal DAB Detection Kit). The specific antibody-enzyme 
complex is then visualized with a precipitating enzyme reaction product. Each step 
is incubated for a precise time and temperature. At the end of each incubation step, 
the VENTANA automated slide stainer washes the sections to stop the reaction and 
to remove unbound material that would hinder the desired reaction in subsequent 
steps. It also applies Liquid Coverslip, which minimizes evaporation of the aqueous 
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b. Step by step procedure 
Table 3.2: Staining protocols for PATHWAY anti-HER2/neu (4B5) with iView DAB 
detection kit 





ULTRA CC1, mild 
Enzyme (Protease) None required 
Antibody (Primary) Approximately 24 minutes, 36
o
C 




Post Counterstain Bluing, 4 minutes 
 
- Apply slide bar code label which corresponds to the antibody protocol to be 
performed. 
- Load the primary antibody, appropriate detection kit dispensers, and 
required accessory reagents onto the reagent tray and place them on the automated 
slide stainer. Check bulk fluids and waste. 
- Load the slides onto the automated slide stainer. 
- Start the staining run. 
- At the completion of the run, remove the slides from the automated slide 
stainer. 
- Wash in a mild dishwashing detergent to remove the coverslip solution. 
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c. Criteria for scoring 
We scored IHC results based on manufacturer's instruction, Interpretation Guide for 
VENTANA anti-HER2/neu (4B5) and the criteria for scoring IHC used in ToGA 
trial [8]. 
Table 3.3: Criteria for intensity and pattern of cell membrane staining in gastric 
carcinoma. Adapted from Interpretation Guide for VENTANA anti-HER2/neu (4B5) 
 
 
Figure 3.1: HER2 IHC classification in gastric and oesophageal junction samples. 
Adapted from Interpretation Guide for VENTANA anti-HER2/neu (4B5)  
21 
 
Van Trung Nghia - Identification of HER2 protein overexpression and gene amplification in gastric cancer - 
Ph.D thesis in Clinical Biochemistry and Clinical Proteomics of  
Ph.D School in Biomolecular and Biotechnological Science - University of Sassari 
 
 
3.6. Immunohistochemical staining for CD20, CD56, Chromogranin A, 
Synaptophysin 
We performed these IHC staining on Ventana Benchmark Ultra automatic staining 
system, similar as with IHC staining for HER2 protein. The results were interpreted 
by experts in Anatomical Pathological Department of Sassari University Hospital 
and Hue University Hospital. 
3.7. Fluorescence in situ hybridyzation for HER2 gene 
FISH for HER2 gene amplification was conducted using the PathVysion HER2 
DNA probe kit (Abbott Molecular Inc). 
a. Preparing Specimen slide 
 - Cut 4 - 6 µm thick paraffin sections using a microtome 
 - Float the sections in a protein-free water bath at 40°C 
 - Mount the section on the positive side of Superfrost slide 
 - Allow slides to air dry 
 - Transfer the mark from the H&E slide to the corresponding areas of the 
unstained slide, marking the glass on the side opposite the tissue section 
 - Bake the unstained slides 2-24 hours at 56 ± 2
o
C 
 - Process the unstained slides following the procedure below 
b. Deparaffinizing slides 
 - Immerse slides in Hemo-De for 5 minutes at room temperature 
 - Repeat twice using new Hemo-De each time 
 - Dehydrate slides in 100% EtOH for 3 minutes at room temperature. Repeat 
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c. Pretreating slides 
 - Immerse slides in Pretreatment Solution at 80±1°C for 30±5 minutes 
 - Immerse slides in purified water for 3 minutes at room temperature 
 - Remove slides from the jar of puriffied water. Remove excess water by 
blotting the edges of the slides on a paper towel 
d. Protease treatment 
 - Immerse slides in Protease Solution at 37±1°C for 10-60 minutes 
 - Immerse slides in puriffied water for 3 minutes at room temperature 
 - Remove slides from the jar of puriffied water. Remove excess water by 
blotting the edges of the slides on a paper towel 
e. Dehydration 
 - Immerse slides in 70% EtOH for 1 minute at room temperature 
 - Immerse slides in 85% EtOH for 1 minute at room temperature 
 - Immerse slides in 100% EtOH for 1 minute at room temperature 
- Drain the excess EtOH from the slide by blotting on a paper towel, and 
wipe the underside of the slide 
- Dry slides on a 45-50
o
C slide warmer for 2-5 minutes 
f. Co-denaturation and hybridization with ThermoBrite 
 - Prewarm the probe to room temperature, vortex to mix and spin down 
 - Apply 10µl of probe to the sample area of the slide 
 - Place a coverslip (22x22 mm) and seal edges with ruber cement 
 - Program ThermoBrite as follow: 
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  + Denaturation: 80
o
C, 5 minutes 
  + Hybridization: 37
o
C, 18 hours 
 - Close the lid and start the program 
g. Post-hybridization wash 
 - Add post-hybridization wash buffer (2X SSC/0.3% NP-40) to a Coplin jar. 
Prewarm the post-hybridization wash buffer by placing the Coplin jar in the 73±1°C 
water bath for at least 30 minutes or until solution temperature has reached 73±1°C. 
 - Add post-hybridization wash buffer to a second Coplin jar and place at 
room temperature 
 - Remove the rubber cement seal from the first slide by gently pulling up on 
the sealant with forceps 
 - Immerse slide(s) in post-hybridization wash buffer at room temperature and 
float off coverslip 
 - After coverslip has been carefully removed, remove excess liquid by 
wicking off the edge of the slide and immerse slide in post-hybridization wash 
buffer at 73±1°C for 2-5 minutes 
 - Remove each slide from the wash bath and air dry in the dark in an upright 
position 
h. Counterstain 
 - Apply 10 µl of DAPI counterstain to the target area of the slide 
 - Apply a 22x22 mm glass coverslip 
 - Store the slides in -20
o
C freezer for at least 30 minutes before viewing 
 - After removing from the -20
o
C freezer, allow slides to reach room 
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i. Signal enumeration 
 - Evaluate slide adequacyusing the following criteria: 
   + Probe Signal Intensity: The signal should be bright, distinct, and 
easily evaluable. Signals should be in either bright, compact, oval shapes or stringy, 
diffuse, oval shapes.  
+ Background: The background should appear dark or black and 
relatively free of fluorescence particles or haziness. 
 - Recognition of target Signals: Use the prescribed filter. Adjust the depth of 
the focus, and become familiar with the size and shape of the target signals and 
noise (debris). Enumerate hybridization signals only among tumor cells. Tumor 
cells in general are larger than normal cells, lymphocytes, and epithelialcells. 
Identify target areas by H & E stain on every 10th slide of the same tissue block. 
Identify these areas on the coverslip after the FISH assay is performed. Use a 25X 
objective to view the hybridized area and locate the target of interest (tumor cells as 
identified by H & E stain). Avoid areas of necrosis and where the nuclear borders 
are ambiguous. Skip those nuclei with signals that require subjective judgment. Skip 
signals with weak intensity and non-specificity, or with noisy background. Skip 
nuclei with insufficient counterstain to determine the nuclear border. Enumerate 
only those nuclei with discrete signals. 
- Signal Enumeration:  
Using a 40X objective, scan several areas of tumor cells to account for possible 
heterogeneity. Select an area of good nuclei distribution; avoid areas of the target 
where hybridization signals are weak. Using a 63X or 100X objective, begin 
analysis in the upper left quadrant of the selected area and, scanning from left to 
right, count the number of signals within the nuclear boundary of each evaluable 
interphase cell according to the guidelines provided.  
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Focus up and down to find all of the signals present in the nucleus. Count two 
signals that are the same size and separated by a distance equal or less than the 
diameter of the signal as one signal. Do not score nuclei with no signals or with 
signals of only one color. Score only those nuclei with one or more FISH signals of 
each color. Record counts in a two-way table. Calculate the ratio between "total of 
HER2 signals" and "total of CEP17 signals" 
 - Result interpretation: 
  + If the ratio is <2, HER2 gene amplification was not observed 
  + If the ratio is ≥2, HER2 gene amplification was observed 
  + If the ratio is 1,8 - 2,2, count another 20 nuclei, and the slide was 
enumerated by another technician to verify the results. If still in doubt, the assay 
was repeated with a fresh specimen slide. 
3.8. Study design 
 
Figure 3.2: Scheme of study design 
All collected samples were stained H&E and interpreted to determine the diagnosis 
of gastric cancer. If the slide was not cancer or not good quality (caused mainly by 
wrong fixation), we excluced the sample. 
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With gastric cancer samples, we did IHC staining of CAM 5.2, CD20, CD56, 
Chromogranin A, Synaptophysin depend on initial gastric cancer diagnosis. 
All samples which were not adenocarcinoma were excluded. The adenocarcinoma 
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4. RESULTS AND DISCUSSION 
 
4.1. Characteristics of Specimens 
We collected total 61 specimens. Characteristics of these specimens are shown in 
the table 4.1 
 
Table 4.1: Characteristics of specimens 
Specimen characteristics Number of cases 
Surgical samples 43 
Biopsy samples 18 
Adenocarcinoma 43 
Lymphoma 2 
Not good H&E quality 10 




There are 43 specimens were diagnosed adenocarcinoma. We have 10 cases that 
were diagnosed as "not good quality". The mainly cause due to wrong fixation time 
(longer 20 minutes after the specimens taked off patient body). We have 6 cases that 
were not gastric cancer, maybe cause by the surgical specimen are not cut correctly 
into the cancer areas. 43 adenocarcinoma samples would be done next steps: IHC 
for HER2 protein and FISH for HER2 gene amplification. 
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Figure 4.1: UDD68, lymphoma (H&E, 20X) 
 
 
Figure 4.2: UDD68, lymphoma (CD20/IHC, 20X) 
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4.2. Characteristics of adenocarcinoma samples 
Characteristics of 43 adenocarcinoma samples are shown in the table 4.2. 
Median patient age was 60 years (range 31–83 years), and the male/female ratio 
was 1,71:1 (24 males, 14 females). There were 23 intestinal adenocarcinomas and 
20 diffuse adenocarcinomas. 
Table 4.2: Characteristics of adenocarcinoma samples 
Characteristics 
Number of cases 
(%) 
Age(years), median (range)  60 (30 – 83) 
Sex 
     Male 
     Female 






     Surgical  





     Intestinal type 
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Figure 4.3: UDD67, adenocarcinoma, intestinal type (H&E, 20X) 
 
 
Figure 4.4: UDD67, adenocarcinoma, intestinal type (CAM 5.2/IHC, 20X) 
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Figure 4.5: UDD47, adenocarcinoma, diffuse type (H&E, 20X) 
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4.3. HER2 protein overexpression 
HER2 is a important marker for identifying patients with advanced gastric cancer 
who respond to trastuzumab-containing regimens. HER2 tests can be applied not 
only to surgically resected specimens but also to endoscopic biopsy specimens. 
Many previous studies that evaluated HER2 status in gastric cancer applied the 
criteria for assessing breast cancer [18, 30, 48, 57]. Generally, the criteria for HER2 
protein overexpression were the same, but there were some differences in the 
methods used to evaluate HER2 status in breast and gastric cancer[49, 58]. 
In the present study, HER2 protein status in 43 gastric adenocarcinoma tissue 
samples was determined with immunohistochemical staining (Figure 4.7) 
 
 
Figure 4.7: UDD66, adenocarcinoma, HER2 3+ (IHC, 40X) 
Of the 43 gastric adenocarcinoma tissue samples, 29 (67,4%) were scored as 0; 9 
(20,9%) as 1+; 3 (6,9%) as 2+, and 2 (4,8%) as 3+. The positive rate 
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HER2 protein status were shown in the table 4.3.  
Table 4.3: HER2 protein overexpression 
HER2  
overexpression 
Number of cases (%) 
Intestinal  Diffuse  Total   
IHC score 
     0 
     1 + 
     2 +  















2 (4.8)  
Total  23  20  43 (100)  
 
The proportion of positive HER2 protein overexpression  cases was 11,7 %. These 
results were comparable with those previously reported [41, 59]. Hofmann and 
coworker maked an meta-analysis of 16 IHC studies containing 3,264 samples and 
reported the mean HER2-positive rate to be 17.6 % (range 6.8–34.0 %) [41]. 
Takehana et al., Kim et al., Barros-Silva et al. reported the HER2 positive rate to be 
8,2%, 6,0%, 9,3%, respectively [22, 34, 60]. In our study, the proportion of positive 
cases were 11,7% higher than 3 those studies. These differents may be dirived from 
the variaion of HER2/IHC scoring. Those studies used old scoring that applied for 
breast cancer, so the proportion is lower. 
In our study, the proportion of positive HER2 cases was 13,2% (3/23) and 10% 
(2/20) in intestinal and diffuse type according to Lauren’s classification, 
respectively. These data are consistant with previous reports that the intestinal type 
showed a higher rate of HER2 positivity than the diffuse type [35, 36, 58, 61, 62]. 
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4.4. HER2 gene amplification 
The HER2/CEP17 ratio was determined using the rate of HER2 signals and CEP17 
signals in 20 nuclei. The total number of HER2 signals was divided by  the total 
number of CEP17 signals, with a ratio was ≥ 2 according to the indications given by 
the Abbott-Vysis Company. 
In our study, FISH assay was technically successful in 40 (93 %) of the 43 gastric 
adenocarcinoma cases. The HER2 gene was judged to be amplified in 3 of 40 cases 
(7,5%) (Figure 4.8). Three FISH failure cases occurred for surgical specimens with 
IHC 0, 1+ and 2+.  Our findings with regard to the prevalence of HER2 gene 
amplification are similar to figures reported in the literature (generally around 6-
30% for gene amplification) [59]. HER2 gene status were showed in the table 4.4.  
Table 4.4: HER2 gene amplification 
HER2 
amplification 
Number of cases (%) 
Intestinal  Diffuse  Total   
FISH 
     positive 









37 (92,5)  
Total  21  19 40 (100)  
 
Some genetic alterations are exclusive of given subtypes of gastric carcinomas, as 
exemplified by CDH1 mutations in diffuse gastric adenocarcinomas [63, 64]. Some 
authors have stated that HER2 amplification is an exclusive event of intestinal type 
gastric carcinomas [34, 65]. However, of the 3 adenocarcinoma cases with 
amplification detected by FISH, one (5%) was diffuse and two were intestinal type 
according to Lauren's classification. Other authors reported that diffuse gastric 
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adenocarcinomas account for 5 – 6% of all diffuse adenocarcinomas which is 
observed by our findings [21, 22, 33]. 
 
Figure 4.8: UDD66, adenocarcinoma, FISH (+),100X 
Conventionally, detecting HER2 gene amplification by FISH is considered the 
reference standard in breast and gastric cancer [42, 66]. However, FISH suffers 
from the following drawbacks: the analysis is labour intensive and time consuming, 
requiring a fluorescence microscope and specific observer training; the photolability 
of the probes mandates storage of data in the form of archival micrographs, which 
necessitate the incorporation of a high-resolution digital camera; and the correlation 
with tumour morphological features, such as tumour heterogeneity, is difficult with 
FISH. In contrast, the analysis of CISH is less time consuming because it can be 
performed with a bright field microscope, yields a more long-lasting record than 






Van Trung Nghia - Identification of HER2 protein overexpression and gene amplification in gastric cancer - 
Ph.D thesis in Clinical Biochemistry and Clinical Proteomics of  
Ph.D School in Biomolecular and Biotechnological Science - University of Sassari 
 
 
4.5. Concordance between IHC and FISH results 





rate (%) Positive  Negative  
     0 
     1 + 
     2 + 














In our study, among 3 FISH positive cases, 1 displayed an HER2 IHC score of 0, 
two displayed a score of 3+ . One cases which showed HER2 gene amplification 
but not HER2 IHC 3+ scores was considered discrepant case. The discordances in 
IHC-negative/FISH-positive cases were mostly attributed to intratumor 
heterogeneity and low-level amplification. So, with HER2 testing, we suggest that 
all of gastric adenocarcinomas patients shoud be tested with IHC and FISH, 
contemporary. 
The concordance rate are 100%, 100% and 96,4% with cases of IHC 3+, 1+ and 0, 
respectively. These rates are very high and similar with many studies. Yano et al.  
found a concordance rate between IHC and FISH in the HER2 protein 
overexpression cases of 87% [18]. In the ToGA trial, the concordance between 
HER2 positivity by IHC and FISH was 87% and differences were largely due to 
FISH-positive cases that were IHC 0/1+ [8]. 
In 2 cases with IHC 2+, one is surgical sample and one is biopsy sample, we have 
no FISH positive case. The result is different with another previous studies [51]. 
The different may be derived from a very small number of our patients or from 
errors of sampling. Warneke et al. evaluated the risk of sampling errors in 
specimens of biopsy size, which may be caused by heterogeneous overexpression of 
HER2 in 454 gastric cancer cases [68]. HER2 test (IHC and FISH) results of tissue 
microarray (TMA) which contained five tissue cylinders were compared with those 
of matched whole tissue sections of resected gastric cancer specimens. Comparison 
of whole tissue sections with corresponding TMAs showed a false negative rate of 
24 % and a false positive rate of 3 % for TMAs. They concluded that assessment of 
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the HER2 status in tissue biopsies carries a significant risk of sampling errors 
rendering patients unsuitable for treatment with trastuzumab. Although their study 
cohort included 51 % of intestinal-type gastric cancer cases, the high discordant rate 
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In summary, we assessed the HER2 status in 43 samples from surgical and biopsy 
cases of gastric cancer.  
The rates of HER2 protein overexpression are 4,8% of IHC 3+; 6,9% of IHC 2+. 
The rate of HER2 gene amplification is 7,5%. 
The concordance between IHC and FISH in testing HER2 status of gastric 
adenocarcinoma is very high but remain 1 dicrepant case. 
We suggest that we should be performed FISH confirmation of any degree of HER2 
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